peptidylprolyl isomerase A pseudogene 50Genealiases: []
Q-omics provides the consensus-scored PPIAP50 profile across patient tissues and cancer cell-line models. PPIAP50 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, PPIAP50 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, PPIAP50 RNA expression shows 5,433 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, BRCA, and ACC as cancer lineages where PPIAP50 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIAP50 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIAP50 survival associations across molecular data types. PPIAP50 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIAP50 RNA expression–survival associations across cancer types. High PPIAP50 expression shows unfavorable associations in STAD, LIHC, COAD, PAAD, ACC and UCEC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for PPIAP50 RNA expression.
This table summarizes PPIAP50 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PPIAP50. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIAP50 shows higher tumor expression in BRCA, LIHC, HNSC, KIRP, LUAD and LUSC. The BRCA box plot shows higher PPIAP50 RNA expression in tumor versus normal tissue (log2 FC = +0.094, t-test p < 0.001).
This table shows molecular features associated with PPIAP50 in patient tissues and cancer cell lines. In patient samples, PPIAP50 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
